The extension of the review process by the EMA could potentially delay the approval of Novo's drugs. This could impact the company's revenues and, consequently, its stock price. The news is highly relevant as it directly involves Novo and its products. The importance is high as the approval of these drugs could significantly affect Novo's financial performance. The confidence in this analysis is high based on the direct relationship between drug approvals and pharmaceutical companies' financial performance.